1	ENTORNO LAW, LLP	
2	Craig M. Nicholas (SBN 178444) Noam Glick (SBN 251582)	
3	Jake W. Schulte (SBN 293777) Janani Natarajan (SBN 346770)	
4	Gianna E. Tirrell (SBN 358788) 225 Broadway, Suite 1900	
	San Diego, California 92101 Tel: (619) 629-0527	
5	Email: craig@entornolaw.com	
6	Email: noam@entornolaw.com Email: jake@entornolaw.com	
7	Email: janani@entornolaw.com Email: gianna@entornolaw.com	
8	0. 71.1.100	
9	Attorneys for Plaintiff Environmental Health Advocates, Inc.	
10		
11	SUPERIOR COURT OF	THE STATE OF CALIFORNIA
12	IN AND FOR THE	COUNTY OF ALAMEDA
13	ENVIRONMENTAL HEALTH ADVOCATES, INC.,	Case No. 24CV104035
14	Plaintiff,	[PROPOSED] CONSENT JUDGMENT
15	V.	(Health & Safety Code § 25249.6 et seq. and Code Civ. Proc. § 664.6)
16	GPT DE LABORATOIRES FRANCAIS-	
17	SORAS, a French simplified joint stock company; GROUPEMENT DES	,
18	LABORATOIRES FRANCAIS SORAS PTE. LTD., a Singapore private limited company;	
19	and DOES 1 through 100, inclusive,	
20	Defendants.	
21		
22		
23		
24		
25		
26		
27		
28		

1. <u>INTRODUCTION</u>

1.1 Parties

This Consent Judgment is entered into by and between Environmental Health Advocates, Inc., ("EHA" or "Plaintiff") and GPT De Laboratoires Français-Soras and GROUPEMENT DES LABORATOIRES FRANÇAIS SORAS PTE. LTD. (together "Defendants" or "GPT") with EHA and GPT each individually referred to as a "Party" and collectively referred to as the "Parties."

1.2 Plaintiff

EHA is a corporation organized in the state of California, acting in the interest of the general public. It seeks to promote awareness of exposures to toxic chemicals and to improve human health by reducing or eliminating hazardous substances contained in consumer products.

1.3 Defendant

GPT employs ten or more individuals and for purposes of this Consent Judgment only, is a "person in the course of doing business" for purposes of the Safe Drinking Water and Toxic Enforcement Act of 1986, Health and Safety Code section 25249.6 et seq. ("Proposition 65").

1.4 General Allegations

EHA alleges that GPT manufactures, imports, sells, and distributes for sale Embryolisse Embryoderme, Embryolisse 24-Hour Miracle Cream, and Embryolisse Softening Hand Cream that contains diethanolamine ("DEA"). EHA further alleges that GPT does so without providing a sufficient health hazard warning as required by Proposition 65 and related Regulations. GPT denies these allegations and asserts that its products are safe and in compliance with all applicable laws, rules and regulations.

1.5 Notice of Violation

On or around April 19, 2024, October 18, 2024, and November 1, 2024, EHA served GPT, the California Attorney General, and all other required public enforcement agencies with 60-Day Notices of Violation of Proposition 65 ("Notices"). The Notices alleged that GPT had violated Proposition 65 by failing to sufficiently warn consumers in California of the health hazards associated with exposures to diethanolamine ("DEA") contained in skin cream products, including but not limited to Embryolisse Embryoderme, Embryolisse 24-Hour Miracle Cream (Lait Crème Concentre), and Embryolisse

Softening Hand Cream manufactured or processed by GPT that allegedly contain DEA and are imported, sold, shipped, delivered, or distributed for sale to consumers in California by Releasees (as defined in section 4.1). No public enforcer has commenced or is otherwise prosecuting an action to enforce the violations alleged in the Notices.

1.6 Product Description

The products covered by this Consent Judgment are skin cream products, including but not limited to Embryolisse Embryoderme, Embryolisse 24-Hour Miracle Cream (Lait Crème Concentre), and Embryolisse Softening Hand Cream manufactured or processed by GPT that allegedly contain DEA and are imported, sold, shipped, delivered, or distributed for sale to consumers in California by Releasees (as defined in section 4.1) ("Covered Products").

1.7 State of the Pleadings

On or around December 20, 2024, and April 16, 2025, EHA filed two Complaints against GPT for the alleged violations of Proposition 65 that are the subject of the Notices ("Complaints").

1.8 No Admission

GPT denies the material factual and legal allegations of the Notices and Complaints and maintains that all of the products it has manufactured, imported, sold, and/or distributed for sale in California, including Covered Products, have been, and are, in compliance with all applicable laws, rules and regulations. Nothing in this Consent Judgment shall be construed as an admission of any fact, finding, conclusion of law, issue of law, or violation of law, nor shall compliance with this Consent Judgment be construed as an admission of any fact, finding, conclusion of law, issue of law, or violation of law. This Section shall not, however, diminish or otherwise affect GPT's obligations, responsibilities, and duties under this Consent Judgment.

1.9 Jurisdiction

For purposes of this Consent Judgment and the Complaints only, the Parties stipulate that this Court has jurisdiction over GPT as to the allegations in the Complaints, that venue is proper in the County of Alameda, and that the Court has jurisdiction to enter and enforce the provisions of this Consent Judgment pursuant to Proposition 65 and Code of Civil Procedure section 664.6.

2 3

4

5 6

7

8 9 10

11

12 13

14

15 16

17

18 19

20

21 22

23

24 25

26

27 28

1.10 **Effective Date**

For purposes of this Consent Judgment, the term "Effective Date" means the date on which this Consent Judgment is approved and entered as a judgment of the Court, as discussed in Section 5.

1.11 **Compliance Date**

For purposes of this Consent Judgment, the term "Compliance Date" means January 1, 2026.

2. INJUNCTIVE RELIEF

2.1 **Reformulation of the Covered Products**

Beginning on the Compliance Date, GPT shall be permanently enjoined from manufacturing, distributing, or directly selling in the State of California any Covered Product that has a DEA content above the Reporting Limit of 10 mg/kg when analyzed pursuant to liquid chromatography/tandem mass spectrometry (LC/MS/MS), inductively coupled mass-spectroscopy (ICP-MS) or other method of analysis utilized by the International Organization for Standardization (ISO) for qualitative and quantitative screening of cosmetics and cosmetic raw materials.

2.2 Clear and Reasonable Warnings

Commencing on the Compliance Date, GPT agrees any Covered Product sold in California, exceeding the Reformulation Standard set forth in section 2.1 above, and which are distributed or directly sold by GPT in the State of California on or after Compliance Date, shall contain a "clear and reasonable" Proposition 65 warning, within the meaning of Section 25249.6 of the Act. GPT agrees that each warning shall be prominently placed with such conspicuousness, as compared with other words, statements, designs, or devices as to render it likely to be seen, read and understood by an ordinary individual under customary conditions before purchase or use. Each warning shall be provided in a manner such that the consumer or user understands to which specific Covered Products the warning applies, and which listed chemical(s) is/are implicated, so as to minimize the risk of consumer confusion.

For purposes of this Settlement Agreement, a clear and reasonable warning for the Covered Products shall consist of a product-specific warning via one or more of the following methods: (1) A posted sign, shelf tag, or shelf sign for the consumer product at each point of display of the product; (2) Any electronic device or process that automatically provides the warning to the purchaser (not

1	applicable to intern	net purchases, which are subject to the provisions of § 25602(b)); (3) A warning	
2	directly affixed to t	the product's label or tag; or (4) A short-form warning on the label that complies	
3	with the content requirements set forth in §§ 25603(b) and 25603(a). Specifically, pursuant to §		
4	25603(a) - (d), one	of the following statements must be utilized:	
5			
6		WARNING:" [or] "CA WARNING:" [or] "CALIFORNIA WARNING:" This product can expose you to chemicals including	
7 8	t	diethanolamine ("DEA"), which is known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.	
9		OR	
10			
11		WARNING:" [or] "CA WARNING:" [or] "CALIFORNIA WARNING: Cancer risk from exposure to diethanolamine ("DEA").	
12		See www.P65Warnings.ca.gov.	
13		OR	
14	SHORT FORM 3)	WARNING:" [or] "CA WARNING:" [or] "CALIFORNIA"	
15		WARNING: Can expose you to diethanolamine ("DEA"), a carcinogen. See www.P65Warnings.ca.gov.	
16		archiogen. See www.r os warnings.ca.gov.	
17			
18	SHORT FORM ON A PRODUCT	OR	
19	MANUFACTUR ED/LABELED	4) AWARNING: Cancer- www.P65Warnings.ca.gov.	
20	PRIOR TO 1/1/28,		
21	REGARDLESS OF DATE OF		
22	SALE	The triangle above shall be yellow on the warning statement. Where the sign,	
23	label, or shelf tag for	for the product is not printed using the color yellow, the symbol may be printed in	
24		he symbol shall be placed to the left of the warning text, in a size no smaller than	
25		ord, "WARNING." A short-form warning must be provided on a product in a type	
26		with Cal. Code Regs Tit. 27, § 25601(c). In no case shall a warning statement	
27	•	overed Products' packaging appear in a type size smaller than 6-point type. Where	

11

12

8

13

15 16

14

17 18

20

21

19

22

2324

252627

28

consumer information about a product in a language other than English, the warning must also be provided in that language in addition to English.

As set forth in Cal. Code Regs. Tit. 27, § 25602(b), to the extent Covered Products are sold online, a warning that complies with the content requirements of Cal. Code Regs Tit. 27, § 25603 must be provided via one of the following methods: (1) A warning on the product display page; (2) A clearly marked hyperlink using the word "WARNING" or the words "CA WARNING" or "CALIFORNIA WARNING" on the product display page that links to the warning; or (3) An otherwise prominently displayed warning provided to the purchaser prior to completing the purchase. If a warning is provided using the short-form label content pursuant to Section 25602(a)(4), the warning provided on the website may use the same content. For purposes of this section, a warning is not prominently displayed if the purchaser must search for it in the general content of the website. For internet purchases made prior to 1/1/28, a retail seller is not responsible under Section 25600.2(e)(4) for conspicuously posting or displaying the new warning online until 60 calendar days after the retailer receives a warning or a written notice under Section 25600.2(b) and (c) which updates a short-form warning compliant with Section 25603(c) with content compliant with Section 25603(b). These requirements extend to any websites under the exclusive control of GPT where Covered Products are sold into California. In addition, GPT shall instruct any third-party website to which it directly sells its Covered Products to include the same online warning, as set forth above, as a condition of selling the Covered Products in California.

There shall be no obligation for GPT to provide a warning for Covered Products that entered the stream of commerce prior to the Compliance Date, and the Section 4 release applies to all such Covered Products.

(i) Changes in Warning Regulations or Statutes

In the event that the Office of Environmental Health Hazard Assessment promulgates one or more regulations requiring or permitting Proposition 65 warning text and/or methods of transmission applicable to the Covered Products and the chemical at issue, which are different than those set forth above, GPT shall be entitled to use, at its discretion, such other warning text and/or method of transmission without being deemed in breach of this Agreement. If regulations or legislation

are enacted providing that Proposition 65 warnings as to diethanolamine ("DEA") in this product are no longer required, Defendant shall move for modification of the agreement pursuant to the modification provision in Section 12.

2.3 Sell-Through Period

Notwithstanding anything else in this Consent Judgment, Covered Products that are manufactured, packaged, or put into commerce on or before December 31, 2025, is executed shall be subject to the release of liability pursuant to this Consent Judgment, without regard to when such Covered Products were, or are in the future, distributed or sold to customers. As a result, the obligations of GPT, or any Releasees (if applicable), stated in this Section 2 do not apply to Covered Products manufactured, packaged, or put into commerce between the date this Agreement is executed and the Compliance Date.

3. MONETARY SETTLEMENT TERMS

3.1 Settlement Amount

GPT shall pay fifty-five thousand dollars (\$55,000) in settlement and total satisfaction of all the claims referred to in the Notices, the Complaints, and this Consent Judgment. This includes civil penalties in the amount of six thousand dollars (\$6,000) pursuant to Health and Safety Code section 25249.7(b) and attorneys' fees and costs in the amount of forty-nine thousand dollars (\$49,000) pursuant to Code of Civil Procedure section 1021.5.

3.2 Civil Penalty

The portion of the settlement attributable to civil penalties shall be allocated according to Health and Safety Code section 25249.12(c)(1) and (d), with seventy-five percent (75%) of the penalty paid to the California Office of Environmental Health Hazard Assessment ("OEHHA"), and the remaining twenty-five percent (25%) of the penalty paid to EHA individually. The six thousand dollars (\$6,000) in civil penalties shall be paid as follows:

- One payment of \$4,500 to OEHHA, due 14 (fourteen) days after the date the Court approves EHA's motion to approve this Consent Judgment.
- One payment of \$1,500 to EHA, due 14 (fourteen) days after the Effective Date.

 All payments owed to EHA shall be delivered to the following address:

1	
2	Environmental Health Advocates 225 Broadway, Suite 2100
3	San Diego, CA 92101
4	All payments owed to OEHHA (EIN: 68-0284486) shall be delivered directly to OEHHA
5	(Memo Line "Prop 65 Penalties") at the following addresses:
6	For United States Postal Service Delivery:
7	Mike Gyurics
8	Fiscal Operations Branch Chief Office of Environmental Health Hazard Assessment
9	P.O. Box 4010 Sacramento, CA 95812-4010
10	For Federal Express 2-Day Delivery:
11	Mike Gyurics Fiscal Operations Propal Chief
12	Fiscal Operations Branch Chief Office of Environmental Health Hazard Assessment 1001 I Street
13	Sacramento, CA 95814
14	GPT agrees to provide EHA's counsel with a copy of the check payable to OEHHA,
15	simultaneous with its penalty payment to EHA.
16	Plaintiff and its counsel will provide completed IRS 1099, W-9, or other tax forms as required.
17	Relevant information is set out below:
18	• "Environmental Health Advocates, Inc." (EIN: 84-2322975) at the address provided above.
19	• "Office of Environmental Health Hazard Assessment" 1001 I Street, Sacramento, CA 95814.
20	All payments referenced in this section shall be paid within fourteen (14) days of the date the Court
21	approves EHA's motion to approve this Consent Judgment.
22	3.3 Attorney's Fees and Costs
23	The portion of the settlement attributable to attorneys' fees and costs shall be paid to EHA's
24	counsel, who are entitled to reasonable attorneys' fees and costs incurred by it in this action, including
25	but not limited to investigating potential violations, bringing this matter to GPT's attention, as well as
26	litigating and negotiating a settlement in the public interest.
27	
28	

> 4 5

6

7 8

9 10

11 12

14 15

13

17

16

18 19

20 21

22

23 24

25

26

27

28

GPT shall provide its payment for civil penalty and for attorneys' fees and costs to EHA's counsel by physical check or by electronic means, including wire transfers, at GPT's discretion, as follows: forty-nine thousand dollars (\$49,000) in Attorney's Fees and Costs shall be paid as follows:

One payment of \$49,000, due fourteen (14) days after the date the Court approves EHA's motion to approve this Consent Judgment.

The attorney fee payments shall be made payable to Entorno Law, LLP and delivered to:

Noam Glick Entorno Law, LLP 225 Broadway, Suite 1900 San Diego, CA 92101

4. **CLAIMS COVERED AND RELEASE**

EHA's Public Release of Proposition 65 Claims 4.1

Plaintiff, acting on its own behalf and in the public interest, releases GPT, and its parents, subsidiaries, affiliated entities under common ownership or control, its directors, officers, principals, agents, employees, attorneys, insurers, accountants, predecessors, successors, and assigns ("Defendant Entities"), each entity to whom Defendants directly or indirectly distribute, ship, or sell the Covered Products, including but not limited to downstream distributors, wholesalers, customers, retailers (including but not limited to GPT De Laboratoires Français-Soras), and marketplaces franchisees, franchisors, cooperative members, suppliers, licensees, and licensors, and all of the foregoing entities' owners, directors, officers, agents, principals, employees, attorneys, insurers, accountants, representatives, predecessors, successors, and assigns (collectively referred to as the "Releasees") from all claims for violations of Proposition 65 for exposures to DEA up through the Compliance Date based on exposure to DEA from Covered Products as set forth in the Notice(s). Compliance with the terms of this Consent Judgment constitutes compliance with Proposition 65 with respect to exposures to DEA from Covered Products as set forth in the Notice(s). This Consent Judgment is a full, final, and binding resolution of all claims under Proposition 65 that were or could have been asserted against GPT and/or Releasees for failure to comply with Proposition 65 for alleged exposure to DEA from Covered Products. This release does not extend to any third-party retailers selling the product on a website who, after receiving instruction from GPT to include a warning as set forth above in section 2.2, do not include such a warning.

4.2 EHA's Individual Release of Claims

EHA, in its individual capacity, also provides a release to GPT and/or Releasees, which shall be a full and final accord and satisfaction of, as well as a bar to, all actions, causes of action, obligations, costs, expenses, attorneys' fees, damages, losses, claims, liabilities, and demands of every nature, character, and kind, whether known or unknown, suspected or unsuspected, arising out of alleged or actual exposures to DEA in Covered Products manufactured, imported, sold, or distributed by GPT before the Compliance Date.

4.3 GPT's Release of EHA

GPT on its own behalf, and on behalf of Releasees as well as its past and current agents, representatives, attorneys, successors, and assignees, hereby waives any and all claims against EHA and its attorneys and other representatives, for any and all actions taken or statements made by EHA and its attorneys and other representatives, whether in the course of investigating claims, otherwise seeking to enforce Proposition 65 against them, in this matter or with respect to the Covered Products.

4.4 No Other Known Claims or Violations

EHA and EHA's counsel affirm that they are not presently aware of any actual or alleged violations of Proposition 65 by GPT or for which GPT bears legal responsibility other than those that are fully resolved by this Consent Judgment.

5. <u>COURT APPROVAL</u>

This Consent Judgment is not effective until it is approved by the Court and shall be null and void if it is not approved by the Court within one year after it has been fully executed by the Parties, or by such additional time as the Parties may agree to in writing.

6. SEVERABILITY

Subsequent to the Court's approval and entry of this Consent Judgment, if any provision is held by a court to be unenforceable, the validity of the remaining provisions shall not be adversely affected. [Rest of page intentionally left blank.]



7. GOVERNING LAW

The terms of this Consent Judgment shall be governed by the laws of the state of California as applied within the state of California. In the event that Proposition 65 is repealed, or is otherwise rendered inapplicable for reasons, including but not limited to changes in the law; or in the event the California Office of Health Hazard Assessment adopts a regulation or safe use determination, or issues an interpretive guideline that exempts Covered Products from meeting the requirements of Proposition 65; or if DEA cases are permanently enjoined by a court of competent jurisdiction; or if Proposition 65 is determined to be preempted by federal law or a burden on First Amendment rights with respect to DEA in Covered Products or Covered Products substantially similar to Covered Products, then GPT may seek relief from the injunctive obligations imposed by this Consent Judgment to the extent any Covered Products are so affected by modifying the agreement via the mechanisms set forth in Section 12.

8. <u>ENFORCEMENT</u>

In any action to enforce the terms of this Consent Judgment, the prevailing party shall be entitled to its reasonable attorneys' fees and costs. The injunctive terms of this Consent Judgment may be enforced by public agency prosecutors pursuant to California Health and Safety Code section 25249.7(c), and/or by private party prosecutors acting "in the public interest" under California Health and Safety Code section 25249.7(d).

9. NOTICE

Unless otherwise specified herein, all correspondence and notice required by this Consent Judgment shall be in writing and sent by: (i) personal delivery; (ii) first-class, registered, or certified mail, return receipt requested; or (iii) a recognized overnight courier; and (iv) with a copy by email; to the following addresses:

T A	100	~	700
1+	+0	(-) I .
	1()	V 11	_

If to EHA:

Felicia Leborgne Nowels Akerman LLP 201 E. Park Ave., Suite 300 Tallahassee, FL 32301 felicia.nowels@akerman.com Noam Glick Entorno Law, LLP 225 Broadway, Suite 2100 San Diego, CA 92101 noam@entornolaw.com

83076491;1

Any Party may, from time to time, specify in writing to the other, a change of address to which notices and other communications shall be sent.

10. COUNTERPARTS; DIGITAL SIGNATURES

This Consent Judgment may be executed in counterparts and by facsimile signature, each of which shall be deemed an original, and all of which, when taken together, shall constitute one and the same document.

11. POST EXECUTION ACTIVITIES

EHA agrees to comply with the reporting form requirements referenced in Health and Safety Code section 25249.7(f). The Parties further acknowledge that, pursuant to Health and Safety Code section 25249.7(f), a noticed motion is required to obtain judicial approval of the settlement, which motion EHA shall draft and file. In furtherance of obtaining such approval, the Parties agree to mutually employ their reasonable best efforts, including those of their counsel, to support the entry of this agreement as judgment, and to obtain judicial approval of their settlement in a timely manner. For purposes of this Section, "best efforts" shall include, at a minimum, supporting the motion for approval, responding to any objection that any third-party may make, and appearing at the hearing before the Court if so requested.

12. MODIFICATION

This Consent Judgment may be modified by: (i) a written agreement of the Parties and entry of a modified consent judgment thereon by the Court; or (ii) a successful motion or application of any Party, and the entry of a modified consent judgment thereon by the Court.

13. **AUTHORIZATION**

The undersigned are authorized to execute this Consent Judgment and acknowledge that they have read, understand, and agree to all of the terms and conditions contained herein.

14. GOOD FAITH ATTEMPT TO RESOLVE DISPUTES

If a dispute arises with respect to either Party's compliance with the terms of this Consent Judgment entered by the Court, the Parties shall meet and confer in person, or by telephone, and/or in writing and endeavor to resolve the dispute in an amicable manner. No action or motion may be filed in the absence of such a good faith attempt to resolve the dispute beforehand.

ENTIRE AGREEMENT 15. 1 This Consent Judgment contains the sole and entire agreement and understanding of the Parties 2 with respect to the entire subject matter herein, and any and all prior discussions, negotiations, 3 commitments, and understandings related hereto. No representations, oral or otherwise, express or 4 implied, other than those contained herein have been made by any Party. No other agreements, oral or 5 otherwise, unless specifically referred to herein, shall be deemed to exist or to bind any Party. 6 7 **AGREED TO: AGREED TO:** 8 Date: October 8, 2025 9 10 11 **ENVIRONMENTAL HEALTH** GPT DE LABORATOIRES FRANCAIS-ADVOCATES, INC. SORAS AND GROUPEMENT DES 12 LABORATOIRES FRANCAIS SORAS PTE. LTD 13 14 IT IS SO ORDERED. 15 16 Date: __ 17 JUDGE OF THE SUPERIOR COURT 18 19 20 21 22 23 24 25 26 27 28

Au